30,639 LeMaitre Vascular, Inc. $LMAT Shares Purchased by Bridge City Capital LLC

Key Points

• Bridge City Capital increased its LeMaitre Vascular stake by 35.5%, purchasing 30,639 shares to own 116,980 shares valued at approximately $9.66 million. Institutional investors collectively hold 84.64% of LMAT.
• LeMaitre Vascular’s shares opened at $80.94, near the lower end of their 52-week range, while the company’s latest quarterly results fell short of analyst expectations for both earnings and revenue despite 9.6% year-over-year revenue growth.
• Analyst sentiment has weakened, with several firms downgrading the stock and Wells Fargo cutting its price target to $94. The consensus rating is Hold, with an average target price of $110.60.

Bridge City Capital LLC boosted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 35.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,980 shares of the medical instruments supplier's stock after buying an additional 30,639 shares during the quarter. LeMaitre Vascular makes up approximately 2.0% of Bridge City Capital LLC's portfolio, making the stock its 7th largest holding. Bridge City Capital LLC owned approximately 0.51% of LeMaitre Vascular worth $9,661,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. ProShare Advisors LLC lifted its position in LeMaitre Vascular by 36.2% in the third quarter. ProShare Advisors LLC now owns 102,571 shares of the medical instruments supplier's stock valued at $8,471,000 after acquiring an additional 27,270 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in LeMaitre Vascular during the third quarter worth approximately $352,000. Gibbs Wealth Management boosted its stake in shares of LeMaitre Vascular by 6.4% during the 3rd quarter. Gibbs Wealth Management now owns 10,116 shares of the medical instruments supplier's stock valued at $835,000 after buying an additional 607 shares during the last quarter. Sterling Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 844.2% during the third quarter. Sterling Capital Management LLC now owns 727 shares of the medical instruments supplier's stock worth $60,000 after purchasing an additional 650 shares during the period. Finally, Yousif Capital Management LLC raised its stake in LeMaitre Vascular by 18.0% during the 3rd quarter. Yousif Capital Management LLC now owns 6,691 shares of the medical instruments supplier's stock valued at $553,000 after acquiring an additional 1,019 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $80.94 on Monday. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. LeMaitre Vascular, Inc. has a twelve month low of $78.22 and a twelve month high of $118.01. The firm has a market capitalization of $1.85 billion, a P/E ratio of 28.40, a price-to-earnings-growth ratio of 2.33 and a beta of 0.51. The stock's fifty day simple moving average is $81.20 and its 200 day simple moving average is $94.19.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%. LeMaitre Vascular's quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.60 earnings per share. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current year.

Analysts Set New Price Targets

LMAT has been the topic of a number of research analyst reports. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Wall Street Zen downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Zacks Research lowered shares of LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Wells Fargo & Company lowered their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 5th. Finally, Weiss Ratings downgraded shares of LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, October 23rd. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of "Hold" and a consensus target price of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.